IPEC likes what China's doing with excipients; Ranbaxy reports surprise loss;

> A 140% surge in North American sales, driven by its generic Lipitor, was not enough to keep Ranbaxy Laboratories from reporting a quarterly loss. Story

> Uganda has banned 67 drugs from Indian maker Flamingo, claiming that they are substandard. Story

> CVS Caremark ($CVS) realized an 18.4% earnings jump in the last quarter, having grabbed business during the Walgreen ($WAG), Express Scripts ($ESRX) fight. Story

> New guidelines from China's State Food and Drug Administration (SFDA) for excipients has impressed The International Pharmaceutical Excipients Council (IPEC) Americas, which says they are consistent with its own guidelines. Story

And Finally... University of Central Florida scientists think they have stumbled upon a simpler and more efficient way to mass produce the structured nanoparticles used for drug delivery and production. Story

Suggested Articles

Fujifilm Diosynth Biotechnologies last year committed 10 billion yen toward its manufacturing operations. It has now kicked off one of those projects.

Popular logic says you never switch horses, or CDMOs, in the middle of the stream, but Acacia Pharma had to do that to win an FDA approval.

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.